Modality
ASO
MOA
EZH2i
Target
PLK4
Pathway
Incretin
ThymomaCKDWM
Development Pipeline
Preclinical
Nov 2019
→ Nov 2026
PreclinicalCurrent
NCT08728803
662 pts·Thymoma
2022-06→2026-11·Not yet recruiting
NCT07925960
807 pts·CKD
2019-11→TBD·Terminated
1,469 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-11-067mo awayInterim· Thymoma
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
Preclinical
Termina…
Preclinical
Not yet…
Catalysts
Interim
2026-11-06 · 7mo away
Thymoma
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08728803 | Preclinical | Thymoma | Not yet recr... | 662 | HAM-D |
| NCT07925960 | Preclinical | CKD | Terminated | 807 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| Peminaritide | Sarepta | NDA/BLA | PLK4 | |
| Pexaosocimab | United Therapeutics | NDA/BLA | PLK4 | |
| ASN-7038 | Ascendis Pharma | Phase 3 | VEGF | |
| ILM-2412 | Illumina | Phase 3 | PLK4 | |
| ROI-3353 | Roivant Sciences | Phase 1/2 | PLK4 | |
| Liratinib | Krystal Biotech | NDA/BLA | TIM-3 |